MariTide: The Once-Monthly Weight-Loss Shot in Testing
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
MariTide is an experimental weight-loss injection that aims to do something the current shots cannot: work with a single dose once a month instead of once a week. In a mid-stage trial it helped people lose up to about 20% of their body weight (Yale School of Medicine), and it has now entered the final stage of testing. It is not approved and you cannot get it yet, but it is one of the most closely watched names in the next wave of obesity treatment (Amgen).
Who This Helps
This is for anyone tracking what is coming next in weight-loss medicine, especially people who dislike weekly injections and wonder whether a monthly option is on the way. It is also for caregivers who want to know what is real today versus what is still in trials.
What Makes MariTide Different?
MariTide is designed as a once-monthly shot under the skin because it uses an antibody structure that keeps it working in the body for about three to three-and-a-half months, roughly three times longer than today's weekly GLP-1 medicines (Amgen).
It also works through two pathways at once. MariTide blocks the GIP receptor, a hormone pathway tied to insulin signaling and fat storage, while activating the GLP-1 receptor that curbs appetite, a different combination than the GLP-1 drugs on the market now.
What the Trials Found
In a Phase 2 study, the mid-stage testing that checks whether a drug works and is reasonably safe, people without diabetes lost up to about 20% of their body weight, compared with 2.6% on a placebo, and people with type 2 diabetes lost up to about 17% (Amgen).
Researchers described the once-monthly results as promising for people both with and without diabetes, while noting that the findings still need to be confirmed in larger studies (Yale School of Medicine).
Where MariTide Is Now
MariTide has moved into Phase 3, the large final stage where a drug is studied in thousands of people over a longer time before the FDA reviews it for approval. The program, called MARITIME, includes separate studies for obesity and for type 2 diabetes, and the company is exploring uses in heart, kidney, and sleep-apnea conditions (Amgen).
What this means for you: this is a promising update, but you’re still a long way from seeing it available from a provider. Even in the best case, large trials and an FDA review take time, so MariTide is a candidate to watch rather than an option to ask your doctor about today.
How It Compares to Today's Weekly Shots
The pitch is convenience, not necessarily blockbuster changes in outcomes. Today's GLP-1 shots, like Wegovy and Zepbound, are taken weekly and are already FDA approved, while MariTide is built for once a month but is still investigational (Amgen).
What this means for you: MariTide has not been tested head-to-head against the approved weekly brands, so this is about dosing schedule, not proven superiority. If you want fewer needle days someday, it is promising, but the approved options are what deliver results now.
Why a Monthly Option Could Matter
Fewer shots can make treatment easier to stick with, and a big new company entering the field could add competition to a market led by just two makers, which tends to help access over time (BioSpace). It does not guarantee a lower price, and none of it helps until the drug is approved.
While the pipeline develops, the move that helps you now is to weigh what is already available. You can compare today's providers and transparent pricing, including HSA and FSA options, with the GLP Winner provider survey.
Final Takeaway
MariTide is an ambitious bet on a once-a-month weight-loss shot, and its early results earned it a spot in the final round of testing. The medication that will actually impact what options you have today is still a long way off.
For now, news about MariTide is an interesting topic, not a prescription you can get today. Approval, if it comes, is still down the road.
If you want treatment today, weekly shots and daily pills are already approved and effective. The right pick is a conversation for you and your prescriber.
Keep an eye on MariTide as its trials play out, and let it earn its place if the larger studies hold up. Your plan today does not need to wait for it.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
What is MariTide?
MariTide, also called maridebart cafraglutide, is an experimental once-monthly weight-loss injection being developed by Amgen. It is not FDA approved and is still in clinical trials.
How is MariTide different from Ozempic or Wegovy?
MariTide is designed to be taken once a month instead of weekly, and it works through two hormone pathways at once. Today's GLP-1 shots are weekly and already approved, while MariTide is still being studied.
How much weight did people lose on MariTide?
In a mid-stage trial, people without diabetes lost up to about 20% of their body weight and people with type 2 diabetes lost up to about 17%. These are early results that still need to be confirmed in larger studies.
Is MariTide available or FDA approved?
No. MariTide is in Phase 3 trials, the large final studies that come before a company can ask the FDA to approve a drug. There is no set date for when, or whether, it will be available.
When could MariTide be available?
There is no confirmed launch date. Phase 3 trials and an FDA review take time, often years, so MariTide is a candidate to follow rather than an option you can get soon.
Sources
Keep Reading
The Wegovy Pill passed 3 million prescriptions. What $149 self-pay covers, what the 25 mg dose costs, and how the pill compares to the shot.
Insurers and employers are cutting GLP-1 coverage mid-year. See why, how to tell if your plan changed, cash-pay options from $299, and how to appeal.
What the research shows about GLP-1 medications for PCOS, including weight, testosterone, periods, and why it is still an off-label use.
Categories
Curated by
